Vincent Cottin

List of Publications by Citations

390 papers	25,742 citations	71 h-index	154 g-index
568 ext. papers	33,977 ext. citations	8.1 avg, IF	6.98 L-index

#	Paper	IF	Citations
390	Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2014**, 370, 2071-82	59.2	2337
389	An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *American Journal of Respiratory and Critical Care Medicine*, **2013**, 188, 733-48	10.2	2176
388	Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, e44-e68	10.2	1426
387	Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. *Circulation*, **2010**, 122, 156-63	16.7	1035
386	Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. *Pediatric Neurology*, **2013**, 49, 243-54	2.9	916
385	International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. *Journal of Medical Genetics*, **2011**, 48, 73-87	5.8	698
384	Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. *European Respiratory Journal*, **2005**, 26, 586-93	13.6	680
383	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 265-75	10.2	653
382	Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *New England Journal of Medicine*, **2019**, 381, 1718-1727	59.2	585
381	Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference. *Pediatric Neurology*, **2013**, 49, 255-65	2.9	553
380	An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. *European Respiratory Journal*, **2015**, 46, 976-87	13.6	541
379	Pulmonary hypertension due to left heart diseases. *Journal of the American College of Cardiology*, **2013**, 62, D100-8	15.1	437
378	Pulmonary hypertension in chronic lung diseases. *Journal of the American College of Cardiology*, **2013**, 62, D109-16	15.1	390
377	European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. *European Respiratory Journal*, **2010**, 35, 14-26	13.6	351
376	Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. *European Respiratory Journal*, **2010**, 35, 105-11	13.6	303
375	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	298
374	Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. *American Journal of Respiratory and Critical Care Medicine*, **2008**, 178, 948-55	10.2	269

373	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. *European Journal of Internal Medicine*, **2015**, 26, 545-53	3.9	254
372	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(□) trials. *Respiratory Medicine*, **2016**, 113, 74-9	4.6	245
371	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. *European Respiratory Journal*, **2014**, 43, 1691-7	13.6	214
370	Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia. *American Journal of Respiratory and Critical Care Medicine*, **2004**, 169, 994-1000	10.2	203
369	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 147-157	35.1	196
368	The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. *Autoimmunity Reviews*, **2014**, 13, 883-91	13.6	176
367	Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis. *European Respiratory Journal*, **2003**, 22, 245-50	13.6	175
366	MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. *New England Journal of Medicine*, **2018**, 379, 2209-2219	59.2	173
365	The pathogenesis of pulmonary fibrosis: a moving target. *European Respiratory Journal*, **2013**, 41, 1207-18	13.6	172
364	Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients. *American Journal of Respiratory and Critical Care Medicine*, **1998**, 158, 1286-93	10.2	172
363	Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases. *European Respiratory Review*, **2018**, 27,	9.8	168
362	Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: data from the French-Italian HHT network. *Genetics in Medicine*, **2007**, 9, 14-22	8.1	167
361	Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 748-61	10.2	160
360	Characterisation of patients with interstitial pneumonia with autoimmune features. *European Respiratory Journal*, **2016**, 47, 1767-75	13.6	159
359	Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. *Lancet Respiratory Medicine,the*, **2020**, 8, 453-460	35.1	154
358	Eosinophilic pneumonias. *Allergy: European Journal of Allergy and Clinical Immunology*, **2005**, 60, 841-57	9.3	153
357	Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. *Lancet Respiratory Medicine,the*, **2017**, 5, 22-32	35.1	142
356	Pulmonary arteriovenous malformations in hereditary hemorrhagic telangiectasia: a series of 126 patients. *Medicine (United States)*, **2007**, 86, 1-17	1.8	134

355	Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (rendu-osler disease). *Respiration*, **2007**, 74, 361-78	3.7	125
354	Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. *Arthritis and Rheumatism*, **2011**, 63, 295-304		123
353	The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. *PLoS ONE*, **2013**, 8, e70621	3.7	113
352	Pulmonary function in patients receiving long-term low-dose methotrexate. *Chest*, **1996**, 109, 933-8	5.3	109
351	TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients. *Orphanet Journal of Rare Diseases*, **2017**, 12, 2	4.2	107
350	Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease. *BMJ Open Respiratory Research*, **2017**, 4, e000212	5.6	107
349	Pulmonary alveolar proteinosis. *Nature Reviews Disease Primers*, **2019**, 5, 16	51.1	106
348	A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease. An International Working Group Perspective. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1249-1254	10.2	105
347	Spectrum of Fibrotic Lung Diseases. *New England Journal of Medicine*, **2020**, 383, 958-968	59.2	102
346	Revisiting the systemic vasculitis in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): A study of 157 patients by the Groupe d'Etudes et de Recherche sur les Maladies Orphelines Pulmonaires and the European Respiratory Society Taskforce on eosinophilic granulomatosis with polyangiitis (Churg-Strauss). *Autoimmunity Reviews*, **2017**, 16, 1-9	13.6	98
345	Combination therapy: the future of management for idiopathic pulmonary fibrosis?. *Lancet Respiratory Medicine,the*, **2014**, 2, 933-942	35.1	97
344	Lymphangioleiomyomatosis Diagnosis and Management: High-Resolution Chest Computed Tomography, Transbronchial Lung Biopsy, and Pleural Disease Management. An Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1337-1348	10.2	97
343	The impact of emphysema in pulmonary fibrosis. *European Respiratory Review*, **2013**, 22, 153-7	9.8	97
342	The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. *Arthritis and Rheumatology*, **2018**, 70, 1544-1554	9.5	97
341	Heterozygous RTEL1 mutations are associated with familial pulmonary fibrosis. *European Respiratory Journal*, **2015**, 46, 474-85	13.6	96
340	Fibrosing interstitial lung diseases: knowns and unknowns. *European Respiratory Review*, **2019**, 28,	9.8	92
339	Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	89
338	Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. *Thorax*, **2011**, 66, 226-31	3.3	88

337	Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. *Advances in Therapy*, **2014**, 31, 375-91	4.1	87
336	Cryptogenic organizing pneumonia. *Seminars in Respiratory and Critical Care Medicine*, **2012**, 33, 462-75	3.9	87
335	Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. *European Respiratory Journal*, **2009**, 33, 1053-61	13.6	85
334	Initial dual oral combination therapy in pulmonary arterial hypertension. *European Respiratory Journal*, **2016**, 47, 1727-36	13.6	85
333	Interstitial pneumonia with autoimmune features: Clinical, radiologic, and histological characteristics and outcome in a series of 57 patients. *Respiratory Medicine*, **2017**, 123, 56-62	4.6	84
332	The syndrome of combined pulmonary fibrosis and emphysema. *Chest*, **2009**, 136, 1-2	5.3	83
331	Interstitial lung disease associated with systemic sclerosis (SSc-ILD). *Respiratory Research*, **2019**, 20, 13	7.3	80
330	Idiopathic inflammatory myopathies and the lung. *European Respiratory Review*, **2015**, 24, 216-38	9.8	80
329	Churg-Strauss syndrome. *Allergy: European Journal of Allergy and Clinical Immunology*, **1999**, 54, 535-51	9.3	80
328	Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis. *Thorax*, **2018**, 73, 145-150	7.3	79
327	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respiratory Medicine,the*, **2020**, 8, 925-934	35.1	77
326	Prevalence and characteristics of TERT and TERC mutations in suspected genetic pulmonary fibrosis. *European Respiratory Journal*, **2016**, 48, 1721-1731	13.6	77
325	Severe hematologic complications after lung transplantation in patients with telomerase complex mutations. *Journal of Heart and Lung Transplantation*, **2015**, 34, 538-46	5.8	74
324	Eosinophilic Lung Diseases. *Clinics in Chest Medicine*, **2016**, 37, 535-56	5.3	74
323	Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. *Chest*, **2011**, 140, 1016-1024	5.3	73
322	Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. *Medicine (United States)*, **2007**, 86, 181-193	1.8	73
321	ANCA-associated lung fibrosis: analysis of 17 patients. *Respiratory Medicine*, **2008**, 102, 1392-8	4.6	72
320	Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis. *European Respiratory Review*, **2015**, 24, 58-64	9.8	71

319	Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. *European Respiratory Journal*, **2014**, 44, 523-7	13.6	71
318	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia syndrome. *European Respiratory Journal*, **2016**, 47, 1829-41	13.6	70
317	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. *European Respiratory Journal*, **2017**, 50,	13.6	69
316	Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2014**, 108, 1023-30	4.6	69
315	The natural history of progressive fibrosing interstitial lung diseases. *European Respiratory Journal*, **2020**, 55,	13.6	67
314	Everolimus for the treatment of lymphangioleiomyomatosis: a phase II study. *European Respiratory Journal*, **2015**, 46, 783-94	13.6	65
313	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. *Current Medical Research and Opinion*, **2019**, 35, 2015-2024	2.5	65
312	CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab. *European Respiratory Journal*, **2015**, 46, 1740-50	13.6	64
311	TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. *Orphanet Journal of Rare Diseases*, **2018**, 13, 157	4.2	64
310	Epilepsy in tuberous sclerosis complex: Findings from the TOSCA Study. *Epilepsia Open*, **2019**, 4, 73-84	4	63
309	The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 Cases. *Medicine (United States)*, **2013**, 92, e1-e9	1.8	62
308	Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole. *Annals of Oncology*, **1999**, 10, 809-15	10.3	62
307	Cough in idiopathic pulmonary fibrosis. *European Respiratory Review*, **2016**, 25, 278-86	9.8	62
306	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. *Lancet Respiratory Medicine,the*, **2019**, 7, 780-790	35.1	61
305	Chronic eosinophilic pneumonia after radiation therapy for breast cancer. *European Respiratory Journal*, **2004**, 23, 9-13	13.6	61
304	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). *European Respiratory Journal*, **2016**, 48, 1429-1441	13.6	61
303	Combined pulmonary fibrosis and emphysema syndrome associated with familial SFTPC mutation. *Thorax*, **2011**, 66, 918-9	7.3	59
302	Anti-IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss): Data on Seventeen Patients. *Arthritis and Rheumatology*, **2016**, 68, 2274-82	9.5	59

301	Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. *European Respiratory Journal*, **2012**, 40, 630-40	13.6	58
300	Hemorrhagic hereditary telangiectasia (Rendu-Osler disease) and infectious diseases: an underestimated association. *Clinical Infectious Diseases*, **2007**, 44, 841-5	11.6	58
299	Predictors of progression in systemic sclerosis patients with interstitial lung disease. *European Respiratory Journal*, **2020**, 55,	13.6	52
298	Effect of Emphysema Extent on Serial Lung Function in Patients with Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 1162-1171	10.2	51
297	Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. *European Respiratory Review*, **2014**, 23, 193-214	9.8	51
296	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *European Respiratory Journal*, **2017**, 50,	13.6	50
295	Interstitial lung disease associated with anti-PM/Scl or anti-aminoacyl-tRNA synthetase autoantibodies: a similar condition?. *Journal of Rheumatology*, **2010**, 37, 1000-9	4.1	50
294	Idiopathic interstitial pneumonias with connective tissue diseases features: A review. *Respirology*, **2016**, 21, 245-58	3.6	49
293	Central nervous system involvement in eosinophilic granulomatosis with polyangiitis (Churg-Strauss): Report of 26 patients and review of the literature. *Autoimmunity Reviews*, **2017**, 16, 963-969	13.6	49
292	Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment. *European Respiratory Review*, **2014**, 23, 106-10	9.8	49
291	Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. *Autoimmunity Reviews*, **2019**, 18, 113-122	13.6	49
290	Neglected evidence in idiopathic pulmonary fibrosis: from history to earlier diagnosis. *European Respiratory Journal*, **2013**, 42, 916-23	13.6	48
289	Right isovolumic contraction velocity predicts survival in pulmonary hypertension. *Journal of the American Society of Echocardiography*, **2013**, 26, 297-306	5.8	47
288	Combined pulmonary fibrosis and emphysema in connective tissue disease. *Current Opinion in Pulmonary Medicine*, **2012**, 18, 418-27	3	47
287	Different phenotypes in dermatomyositis associated with anti-MDA5 antibody: Study of 121 cases. *Neurology*, **2020**, 95, e70-e78	6.5	46
286	TOSCA - first international registry to address knowledge gaps in the natural history and management of tuberous sclerosis complex. *Orphanet Journal of Rare Diseases*, **2014**, 9, 182	4.2	46
285	Effectiveness of cladribine therapy in patients with pulmonary Langerhans cell histiocytosis. *Orphanet Journal of Rare Diseases*, **2014**, 9, 191	4.2	46
284	Lung cancer in combined pulmonary fibrosis and emphysema: a series of 47 Western patients. *Journal of Thoracic Oncology*, **2014**, 9, 1162-70	8.9	45

283	Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study. *ERJ Open Research*, **2018**, 4,	3.5	45
282	Anti-elastin autoantibodies are not present in combined pulmonary fibrosis and emphysema. *European Respiratory Journal*, **2009**, 33, 219-21	13.6	42
281	Alveolar hemorrhage in vasculitis: primary and secondary. *Seminars in Respiratory and Critical Care Medicine*, **2011**, 32, 310-21	3.9	41
280	Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	40
279	Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. *European Respiratory Review*, **2017**, 26,	9.8	39
278	The Lung in Hereditary Hemorrhagic Telangiectasia. *Respiration*, **2017**, 94, 315-330	3.7	39
277	Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. *Orphanet Journal of Rare Diseases*, **2017**, 12, 95	4.2	39
276	Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. *Allergy: European Journal of Allergy and Clinical Immunology*, **2009**, 64, 589-95	9.3	38
275	Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. *Respiratory Medicine*, **2005**, 99, 511-4	4.6	38
274	Urinary eosinophil-derived neurotoxin/protein X: a simple method for assessing eosinophil degranulation in vivo. *Journal of Allergy and Clinical Immunology*, **1998**, 101, 116-23	11.5	38
273	Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2017**, 50,	13.6	37
272	Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. *Thorax*, **2009**, 64, 274-5	7.3	37
271	Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. *PLoS ONE*, **2017**, 12, e0166462	3.7	37
270	Widening the landscape of heritable pulmonary hypertension mutations in paediatric and adult cases. *European Respiratory Journal*, **2019**, 53,	13.6	37
269	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. *European Respiratory Journal*, **2018**, 52,	13.6	37
268	Significance of connective tissue diseases features in pulmonary fibrosis. *European Respiratory Review*, **2013**, 22, 273-80	9.8	36
267	A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials. *European Respiratory Journal*, **2015**, 46, 243-9	13.6	35
266	Genetics of idiopathic pulmonary fibrosis: from mechanistic pathways to personalised medicine. *Journal of Medical Genetics*, **2017**, 54, 93-99	5.8	34

265	Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study. *Lancet Respiratory Medicine,the*, **2019**, 7, 771-779	35.1	34
264	Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. *Autoimmunity Reviews*, **2018**, 17, 653-659	13.6	34
263	Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study). *European Respiratory Journal*, **2021**, 57,	13.6	34
262	Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial. *BMJ Open Respiratory Research*, **2018**, 5, e000289	5.6	34
261	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1146-1153	10.2	33
260	Renal angiomyolipoma in patients with tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increase disease Awareness. *Nephrology Dialysis Transplantation*, **2019**, 34, 502-508	4.3	33
259	Prognostic value of right ventricular ejection fraction in pulmonary arterial hypertension. *European Respiratory Journal*, **2015**, 45, 139-49	13.6	32
258	Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. *European Respiratory Review*, **2012**, 21, 161-7	9.8	32
257	Alveolar Hemorrhage in Vasculitis (Primary and Secondary). *Seminars in Respiratory and Critical Care Medicine*, **2018**, 39, 482-493	3.9	32
256	Eosinophilic lung diseases. *Immunology and Allergy Clinics of North America*, **2012**, 32, 557-86	3.3	31
255	Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. *American Journal of Respiratory and Critical Care Medicine*, **2005**, 172, 1605; author reply 1605-6	10.2	31
254	Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS). *Clinical and Experimental Rheumatology*, **2017**, 35 Suppl 106, 75-81	2.2	31
253	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. *Respiration*, **2018**, 95, 317-326	3.7	29
252	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version. *Revue Des Maladies Respiratoires*, **2017**, 34, 900-968	0	28
251	Exome sequencing and pathogenicity-network analysis of five French families implicate mTOR signalling and autophagy in familial sarcoidosis. *European Respiratory Journal*, **2019**, 54,	13.6	28
250	Portopulmonary hypertension in the current era of pulmonary hypertension management. *Journal of Hepatology*, **2020**, 73, 130-139	13.4	28
249	Rare lung disease and orphan drug development. *Lancet Respiratory Medicine,the*, **2013**, 1, 479-87	35.1	28
248	Hypereosinophilic obliterative bronchiolitis: a distinct, unrecognised syndrome. *European Respiratory Journal*, **2013**, 41, 1126-34	13.6	28

247	Interstitial lung disease. *European Respiratory Review*, **2013**, 22, 26-32	9.8	28
246	Acute exacerbation of idiopathic pulmonary fibrosis: a clinical review. *Internal and Emergency Medicine*, **2015**, 10, 401-11	3.7	26
245	Churg-Strauss syndrome presenting with acute myocarditis and cardiogenic shock. *Heart Lung and Circulation*, **2012**, 21, 178-81	1.8	26
244	Long-term follow-up in 12 children with pulmonary arteriovenous malformations: confirmation of hereditary hemorrhagic telangiectasia in all cases. *Journal of Pediatrics*, **2007**, 151, 299-306	3.6	26
243	Safety and efficacy of pirfenidone in patients carrying telomerase complex mutation. *European Respiratory Journal*, **2018**, 51,	13.6	25
242	The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. *Respiratory Research*, **2013**, 14 Suppl 1, S5	7.3	25
241	Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH) Syndrome and Carcinoid Tumors With/Without NECH: A Clinicopathologic, Radiologic, and Immunomolecular Comparison Study. *American Journal of Surgical Pathology*, **2018**, 42, 646-655	6.7	24
240	Right-to-left shunt with hypoxemia in pulmonary hypertension. *BMC Cardiovascular Disorders*, **2009**, 9, 15	2.3	24
239	Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. *PLoS ONE*, **2018**, 13, e0197112	3.7	24
238	Urinary eosinophil-derived neurotoxin in Churg-Strauss syndrome. *Journal of Allergy and Clinical Immunology*, **1995**, 96, 261-4	11.5	23
237	Regulator of telomere length 1 () mutations are associated with heterogeneous pulmonary and extra-pulmonary phenotypes. *European Respiratory Journal*, **2019**, 53,	13.6	23
236	A step-wise approach for establishing a multidisciplinary team for the management of tuberous sclerosis complex: a Delphi consensus report. *Orphanet Journal of Rare Diseases*, **2019**, 14, 91	4.2	22
235	Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. *European Respiratory Review*, **2014**, 23, 225-30	9.8	22
234	Conditions associated with severe carbon monoxide diffusion coefficient reduction. *Respiratory Medicine*, **2011**, 105, 1248-56	4.6	22
233	Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. *European Respiratory Journal*, **2010**, 36, 202-4	13.6	22
232	demonstration of pulmonary microvascular involvement in COVID-19 using dual-energy computed tomography. *European Respiratory Journal*, **2020**, 56,	13.6	22
231	Interstitial Pneumonia With Autoimmune Features (IPAF). *Frontiers in Medicine*, **2019**, 6, 209	4.9	21
230	Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. *Chest*, **2019**, 156, 706-714	5.3	21

229	Whole exome sequencing in three families segregating a pediatric case of sarcoidosis. *BMC Medical Genomics*, **2018**, 11, 23	3.7	21
228	L5. Eosinophilic granulomatosis with polyangiitis (Churg-Strauss). *Presse Medicale*, **2013**, 42, 507-10	2.2	21
227	Familial vs. sporadic sarcoidosis: BTNL2 polymorphisms, clinical presentations, and outcomes in a French cohort. *Orphanet Journal of Rare Diseases*, **2016**, 11, 165	4.2	20
226	Connective tissue diseases, multimorbidity and the ageing lung. *European Respiratory Journal*, **2016**, 47, 1535-58	13.6	20
225	Lung function outcomes in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2019**, 146, 42-48	4.6	20
224	Pulmonary varix mimicking pulmonary arteriovenous malformation in a patient with Turner syndrome. *Respiration*, **2007**, 74, 110-3	3.7	19
223	Combined pulmonary fibrosis and emphysema in systemic sclerosis: A syndrome associated with heavy morbidity and mortality. *Seminars in Arthritis and Rheumatism*, **2019**, 49, 98-104	5.3	19
222	Risk Factors for Mortality after COVID-19 in Patients with Preexisting Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 245-249	10.2	19
221	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. *European Respiratory Journal*, **2020**, 55,	13.6	18
220	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. *Chest*, **2020**, 157, 1506-1512	5.3	18
219	Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study. *Arthritis and Rheumatology*, **2021**, 73, 498-503	9.5	18
218	Lung Diseases in Inflammatory Myopathies. *Seminars in Respiratory and Critical Care Medicine*, **2019**, 40, 255-270	3.9	17
217	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. *ERJ Open Research*, **2019**, 5,	3.5	17
216	Non-severe eosinophilic granulomatosis with polyangiitis: long-term outcomes after remission-induction trial. *Rheumatology*, **2019**, 58, 2107-2116	3.9	16
215	The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis. *Expert Opinion on Drug Safety*, **2017**, 16, 857-865	4.1	15
214	Epidemiology, clinical picture and long-term outcomes of FIP1L1-PDGFRA-positive myeloid neoplasm with eosinophilia: Data from 151 patients. *American Journal of Hematology*, **2020**, 95, 1314-1323	7.1	15
213	Usual interstitial pneumonia in ANCA-associated vasculitis: A poor prognostic factor. *Journal of Autoimmunity*, **2020**, 106, 102338	15.5	15
212	Pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia: Correlations between computed tomography findings and cerebral complications. *European Radiology*, **2018**, 28, 1338-1344	3.8	14

211	Patients', relatives', and practitioners' views of pulmonary arterial hypertension: A qualitative study. *Presse Medicale*, **2016**, 45, e11-27	2.2	14
210	The Respiratory System in Autoimmune Vascular Diseases. *Respiration*, **2018**, 96, 12-28	3.7	14
209	Pragmatic prognostic approach of rheumatoid arthritis-associated interstitial lung disease. *European Respiratory Journal*, **2010**, 35, 1206-8	13.6	14
208	Safety and efficacy of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis and carrying a telomere-related gene mutation. *European Respiratory Journal*, **2021**, 57,	13.6	14
207	Clinical Characteristics of Subependymal Giant Cell Astrocytoma in Tuberous Sclerosis Complex. *Frontiers in Neurology*, **2019**, 10, 705	4.1	13
206	Occupational hypersensitivity pneumonitis in a baker: a new cause. *Chest*, **2014**, 145, 856-858	5.3	13
205	Respiratory failure with diffuse bronchiectases and cryoglobulinaemia. *European Respiratory Journal*, **2008**, 31, 1374-8	13.6	13
204	Syndrome of pleural and retrosternal "bridging" fibrosis and retroperitoneal fibrosis in patients with asbestos exposure. *Thorax*, **2008**, 63, 177-9	7.3	13
203	Hypertension art□ielle pulmonaire associ□ aux connectivites. *Revue Des Maladies Respiratoires*, **2006**, 23, 61-72	0	13
202	French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides). *Orphanet Journal of Rare Diseases*, **2020**, 15, 351	4.2	13
201	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 842-854	10.2	13
200	Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK□ trial. *BMJ Open Respiratory Research*, **2018**, 5, e000325	5.6	13
199	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. *European Respiratory Journal*, **2020**, 56,	13.6	12
198	Clinical Genetics of Prolidase Deficiency: An Updated Review. *Biology*, **2020**, 9,	4.9	12
197	Presence of Kidney Disease as an Outcome Predictor in Patients with Pulmonary Arterial Hypertension. *American Journal of Nephrology*, **2018**, 47, 134-143	4.6	12
196	Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. *Respiratory Medicine*, **2019**, 156, 20-25	4.6	12
195	Newly Diagnosed and Growing Subependymal Giant Cell Astrocytoma in Adults With Tuberous Sclerosis Complex: Results From the International TOSCA Study. *Frontiers in Neurology*, **2019**, 10, 821	4.1	12
194	Management of idiopathic pulmonary fibrosis in France: a survey of 1244 pulmonologists. *Respiratory Medicine*, **2014**, 108, 195-202	4.6	12

193	SFTPCMutations in Patients with Familial Pulmonary Fibrosis: Combined with Emphysema?. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1113-1113	10.2	12
192	Estimation of the Prevalence of Progressive Fibrosing Interstitial Lung Diseases: Systematic Literature Review and Data from a Physician Survey. *Advances in Therapy*, **2021**, 38, 854-867	4.1	12
191	Phenotype and outcome of pulmonary arterial hypertension patients carrying a mutation. *European Respiratory Journal*, **2020**, 55,	13.6	11
190	Clinical case: Combined pulmonary fibrosis and emphysema with pulmonary hypertension--clinical management. *BMC Research Notes*, **2013**, 6 Suppl 1, S2	2.3	11
189	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. *Respiratory Medicine*, **2017**, 122 Suppl 1, S10-S13	4.6	11
188	Clonal expansion of T cells in patients with eosinophilic lung disease. *Allergy: European Journal of Allergy and Clinical Immunology*, **2011**, 66, 1506-8	9.3	11
187	Centrilobular emphysema combined with pulmonary fibrosis results in improved survival: a response. *Fibrogenesis and Tissue Repair*, **2011**, 4, 16		11
186	Burden of Illness and Quality of Life in Tuberous Sclerosis Complex: Findings From the TOSCA Study. *Frontiers in Neurology*, **2020**, 11, 904	4.1	11
185	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. *Respiratory Research*, **2021**, 22, 84	7.3	11
184	Translation and validation of the King's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. *Chronic Respiratory Disease*, **2017**, 14, 140-150	3	10
183	Identifying chronic thromboembolic pulmonary hypertension through the French national hospital discharge database. *PLoS ONE*, **2019**, 14, e0214649	3.7	10
182	Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups. *Pulmonary Circulation*, **2018**, 8, 2045894018775056	2.7	10
181	Validation of multidisciplinary diagnosis in IPF. *Lancet Respiratory Medicine,the*, **2018**, 6, 88-89	35.1	10
180	Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water. *European Respiratory Journal*, **2013**, 41, 781-3	13.6	10
179	Infiltrative lung diseases in pregnancy. *Clinics in Chest Medicine*, **2011**, 32, 133-146	5.3	10
178	Milestones in lymphangioleiomyomatosis research. *European Respiratory Review*, **2011**, 20, 3-6	9.8	10
177	Pulmonary arteriovenous malformations in patients with hereditary hemorrhagic telangiectasia: follow-up and pathophysiologic considerations. *Journal of Vascular and Interventional Radiology*, **2007**, 18, 938-9; author reply 939	2.4	10
176	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. *Respiratory Research*, **2020**, 21, 312	7.3	10

175	Pilot experience of multidisciplinary team discussion dedicated to inherited pulmonary fibrosis. *Orphanet Journal of Rare Diseases*, **2019**, 14, 280	4.2	10
174	Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials. *European Respiratory Journal*, **2019**, 53,	13.6	10
173	Risk factors for disease progression in idiopathic pulmonary fibrosis. *Thorax*, **2020**, 75, 78-80	7.3	10
172	Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2021**, 178, 106220	4.6	10
171	Renal involvement in eosinophilic granulomatosis with polyangiitis (EGPA): a multicentric retrospective study of 63 biopsy-proven cases. *Rheumatology*, **2021**, 60, 359-365	3.9	10
170	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. *Arthritis and Rheumatology*, **2021**, 73, 295-304	9.5	10
169	Air travel and incidence of pneumothorax in lymphangioleiomyomatosis. *Orphanet Journal of Rare Diseases*, **2018**, 13, 222	4.2	10
168	A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension. *Annals of the Rheumatic Diseases*, **2016**, 75, 1457-65	2.4	9
167	Lung function in Birt-Hogg-Dubé syndrome: a retrospective analysis of 96 patients. *Orphanet Journal of Rare Diseases*, **2020**, 15, 120	4.2	9
166	Treatment Patterns and Use of Resources in Patients With Tuberous Sclerosis Complex: Insights From the TOSCA Registry. *Frontiers in Neurology*, **2019**, 10, 1144	4.1	9
165	Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey. *ERJ Open Research*, **2015**, 1,	3.5	9
164	Combined pulmonary fibrosis and emphysema syndrome in a patient age 28 years with severe systemic sclerosis. *Journal of Rheumatology*, **2011**, 38, 2082-3	4.1	9
163	Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): A retrospective, multicentric, observational study. *Respiratory Medicine*, **2020**, 172, 106146	4.6	9
162	Impact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertension. *ERJ Open Research*, **2018**, 4,	3.5	9
161	Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Respiratory Medicine,the*, **2021**,	35.1	9
160	A 2-Year Observational Study in Patients Suffering from Idiopathic Pulmonary Fibrosis and Treated with Pirfenidone: A French Ancillary Study of PASSPORT. *Respiration*, **2019**, 98, 19-28	3.7	8
159	Vein Diameter on Unenhanced Multidetector CT Predicts Reperfusion of Pulmonary Arteriovenous Malformation after Embolotherapy. *European Radiology*, **2016**, 26, 2723-9	8	8
158	Natural clusters of tuberous sclerosis complex (TSC)-associated neuropsychiatric disorders (TAND): new findings from the TOSCA TAND research project. *Journal of Neurodevelopmental Disorders*, **2020**, 12, 24	4.6	8

157	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. *European Respiratory Journal*, **2019**, 54,	13.6	8
156	Should Patients With Interstitial Lung Disease Be Seen by Experts?. *Chest*, **2018**, 154, 713-714	5.3	8
155	Nintedanib: a new treatment for idiopathic pulmonary fibrosis. *Clinical Investigation*, **2015**, 5, 621-632		7
154	Lung-limited or lung-dominant variant of eosinophilic granulomatosis with polyangiitis. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2092-2095	5.4	7
153	Prolidase deficiency: a new genetic cause of combined pulmonary fibrosis and emphysema syndrome in the adult. *European Respiratory Journal*, **2020**, 55,	13.6	7
152	Should patients with lymphangioleiomyomatosis undergo screening for meningioma?. *European Respiratory Journal*, **2004**, 24, 888-9	13.6	7
151	A RANDOMIZED PLACEBO CONTROLLED TRIAL ASSESSING THE EFFICACY AND SAFETY OF ETANERCEPT IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). *Chest*, **2005**, 128, 496S	5.3	7
150	Pulmonary alveolar proteinosis following cryptococcal meningitis: a possible cause?. *BMJ Case Reports*, **2018**, 2018,	0.9	7
149	Nonspecific interstitial pneumonia: time to be more specific?. *Current Opinion in Pulmonary Medicine*, **2016**, 22, 450-5	3	7
148	Interstitial pneumonia with autoimmune features: the new consensus-based definition for this cohort of patients should be broadened. *European Respiratory Journal*, **2016**, 47, 1295-6	13.6	7
147	Recent advances in the pathobiology and clinical management of lymphangioleiomyomatosis. *Current Opinion in Pulmonary Medicine*, **2018**, 24, 469-476	3	7
146	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. *Lancet Respiratory Medicine,the*, **2021**, 9, 1065-1076	35.1	7
145	Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody. *European Respiratory Review*, **2015**, 24, 370-2	9.8	6
144	Near-fatal haemorrhage from pulmonary arteriovenous malformation in HHT with increased cardiac output. *European Respiratory Review*, **2009**, 18, 190-2	9.8	6
143	Exogenous lipid pneumonia. *Respiration*, **2008**, 76, 442-3	3.7	6
142	Spectrum and Prognosis of Antineutrophil Cytoplasmic Antibody-associated Vasculitis-related Bronchiectasis: Data from 61 Patients. *Journal of Rheumatology*, **2020**, 47, 1522-1531	4.1	6
141	Renal Manifestations of Tuberous Sclerosis Complex: Key Findings From the Final Analysis of the TOSCA Study Focussing Mainly on Renal Angiomyolipomas. *Frontiers in Neurology*, **2020**, 11, 972	4.1	6
140	Functional assessment and phenotypic heterogeneity of and mutations in interstitial lung diseases and lung cancer. *European Respiratory Journal*, **2020**, 56,	13.6	6

139	The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis. *Journal of Clinical Medicine*, **2021**, 10,	5.1	6
138	Serum and pulmonary uric acid in pulmonary arterial hypertension. *European Respiratory Journal*, **2021**, 58,	13.6	6
137	Diagnostic Features in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review. *Annals of the American Thoracic Society*, **2020**, 17, 1333-1336	4.7	5
136	Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. *ERJ Open Research*, **2020**, 6,	3.5	5
135	Effect of cladribine therapy on lung cysts in pulmonary Langerhans cell histiocytosis. *ERJ Open Research*, **2018**, 4,	3.5	5
134	Health economic evaluation in idiopathic pulmonary fibrosis in France. *Current Medical Research and Opinion*, **2018**, 34, 1731-1740	2.5	5
133	Healthcare pathway and patients' expectations in pulmonary fibrosis. *ERJ Open Research*, **2017**, 3,	3.5	5
132	Pulmonary hypertension-specific therapy in patients with chronic respiratory insufficiency. *European Respiratory Journal*, **2014**, 44, 819-21	13.6	5
131	Interstitial pulmonary amyloidosis. *Respiration*, **2008**, 75, 210	3.7	5
130	Survival Improved in Patients Aged ⩾70 Years With Systemic Sclerosis-Associated Pulmonary Arterial Hypertension During the Period 2006 to 2017 in France. *Chest*, **2020**, 157, 945-954	5.3	5
129	Estimates of epidemiology, mortality and disease burden associated with progressive fibrosing interstitial lung disease in France (the PROGRESS study). *Respiratory Research*, **2021**, 22, 162	7.3	5
128	Impact of lung morphology on clinical outcomes with riociguat in patients with pulmonary hypertension and idiopathic interstitial pneumonia: A post hoc subgroup analysis of the RISE-IIP study. *Journal of Heart and Lung Transplantation*, **2021**, 40, 494-503	5.8	5
127	Concomitant medications and clinical outcomes in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2019**, 54,	13.6	5
126	Characteristics and Long-term Outcomes of Pulmonary Venoocclusive Disease Induced by Mitomycin C. *Chest*, **2021**, 159, 1197-1207	5.3	5
125	Safety of right heart catheterization for pulmonary hypertension in very elderly patients. *Pulmonary Circulation*, **2018**, 8, 2045894018799272	2.7	5
124	Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. *Arthritis and Rheumatology*, **2021**, 74, 295	9.5	5
123	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis: 2017 update. Summary. *Revue Des Maladies Respiratoires*, **2017**, 34, 834-851	0	4
122	Epoprostenol discontinuation in patients with pulmonary arterial hypertension: a complex medical and social problem. *Pulmonary Circulation*, **2018**, 8, 2045893217753352	2.7	4

121	Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America. *BMC Pulmonary Medicine*, **2018**, 18, 5	3.5	4
120	Clinical genetics for the pulmonologist: introduction. *Respiration*, **2007**, 74, 3-7	3.7	4
119	Eosinophilic pneumonia in a patient with breast cancer: idiopathic or not?. *Annals of Allergy, Asthma and Immunology*, **2006**, 97, 557-8; author reply 558	3.2	4
118	Pulmonary hypertension in patients with idiopathic pulmonary fibrosis **2012**, 148-160		4
117	External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry. *European Respiratory Journal*, **2021**,	13.6	4
116	Tuberous Sclerosis Complex-Associated Neuropsychiatric Disorders (TAND): New Findings on Age, Sex, and Genotype in Relation to Intellectual Phenotype. *Frontiers in Neurology*, **2020**, 11, 603	4.1	4
115	Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover. *Respiratory Medicine*, **2021**, 183, 106415	4.6	4
114	Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspective. *ERJ Open Research*, **2016**, 2,	3.5	4
113	Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry. *Respiratory Medicine*, **2020**, 177, 106241	4.6	4
112	Autophagy and Mitophagy-Related Pathways at the Crossroads of Genetic Pathways Involved in Familial Sarcoidosis and Host-Pathogen Interactions Induced by Coronaviruses. *Cells*, **2021**, 10,	7.9	4
111	Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. *European Respiratory Journal*, **2021**,	13.6	4
110	Eosinophilic Lung Diseases **2016**, 1221-1242.e13		3
109	The challenge of criteria for interstitial pneumonia with autoimmune features. *Respiratory Medicine* , **2017**, 127, 67	4.6	3
108	Which Biopsy to Diagnose Interstitial Lung Disease? A Call for Evidence and Unity. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 941-942	10.2	3
107	Digital Lung Auscultation: Will Early Diagnosis of Fibrotic Interstitial Lung Disease Become a Reality?. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 261-263	10.2	3
106	Cost-effectiveness of pirfenidone compared to all available strategies for the treatment of idiopathic pulmonary fibrosis in France. *Journal of Market Access & Health Policy*, **2019**, 7, 1626171	3.7	3
105	Manifestations vasculaires pulmonaires de la maladie de Rendu-Osler. *Revue Des Maladies Respiratoires*, **2006**, 23, 53-66	0	3
104	Pneumopathies interstitielles diffuses idiopathiques. *Encyclopédie Médico-chirurgicale Pneumologie*, **2006**, 3, 1-19		3

103	Nintedanib in idiopathic and secondary pleuroparenchymal fibroelastosis. *Orphanet Journal of Rare Diseases*, **2021**, 16, 419	4.2	3
102	Idiopathic non-necrotizing eosinophilic vasculitis limited to the lung: Part of a complex spectrum. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 2454-2455	5.4	3
101	TuberOus SClerosis registry to increAse disease awareness (TOSCA) Post-Authorisation Safety Study of Everolimus in Patients With Tuberous Sclerosis Complex. *Frontiers in Neurology*, **2021**, 12, 630378	4.1	3
100	Interstitial Lung Disease after COVID-19. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 203, 1314-1315	10.2	3
99	French recommendations for the management of systemic sclerosis. *Orphanet Journal of Rare Diseases*, **2021**, 16, 322	4.2	3
98	Rare manifestations and malignancies in tuberous sclerosis complex: findings from the TuberOus SClerosis registry to increAse disease awareness (TOSCA). *Orphanet Journal of Rare Diseases*, **2021**, 16, 301	4.2	3
97	Pulmonary arterial hypertension in heroin users. *Journal of Heart and Lung Transplantation*, **2016**, 35, 932-4	5.8	3
96	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. *Frontiers in Medicine*, **2021**, 8, 699644	4.9	3
95	Drug-induced interstitial lung disease.. *European Respiratory Journal*, **2022**,	13.6	3
94	Spectral Photon-Counting CT Technology in Chest Imaging.. *Journal of Clinical Medicine*, **2021**, 10,	5.1	3
93	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis´´2017 update. Short-length version. *Revue Des Maladies Respiratoires*, **2017**, 34, 852-899	0	2
92	A Rare Case of an Abdominal Aneurysm in a Patient with Lymphangioleiomyomatosis: A Case Report **2019**, 23,		2
91	Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. *Presse Medicale*, **2020**, 49, 104021	2.2	2
90	Sarcoidosis diagnosed in the elderly: a case-control study. *QJM - Monthly Journal of the Association of Physicians*, **2021**, 114, 238-245	2.7	2
89	Isolated positive anti-SS-B autoantibodies are not related to clinical features of systemic autoimmune diseases: Results from a routine population survey. *PLoS ONE*, **2017**, 12, e0185104	3.7	2
88	Mediastinal lymphangioma in an adult. *Journal of Thoracic and Cardiovascular Surgery*, **2018**, 155, e195-e197	4.9	2
87	The TOSCA Registry for Tuberous Sclerosis-Lessons Learnt for Future Registry Development in Rare and Complex Diseases. *Frontiers in Neurology*, **2019**, 10, 1182	4.1	2
86	When to stop in the quest of formes frustes of connective tissue disease?. *Clinical Rheumatology*, **2007**, 26, 615-6	3.9	2

85	Bosentan et fibrose pulmonaire. *Revue De Medecine Interne*, **2007**, 28, S230-S237	0.1	2
84	Effects of nintedanib in patients with progressive fibrosing ILDs and differing baseline FVC: further analyses of the INBUILD trial **2020**,		2
83	Adult pulmonary Langerhans cell histiocytosis **2019**, 581-584		2
82	Clinical Trials in IPF: What Are the Best Endpoints?. *Respiratory Medicine*, **2019**, 433-453	0.2	2
81	Impact of Lung Biopsy on Lung Function in Idiopathic Pulmonary Fibrosis. *Respiration*, **2020**, 99, 1101-1108	3.7	2
80	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. *European Respiratory Review*, **2021**, 30,	9.8	2
79	Concurrence of 1- and 3-Min Sit-to-Stand Tests with the 6-Min Walk Test in Idiopathic Pulmonary Fibrosis. *Respiration*, **2021**, 100, 571-579	3.7	2
78	Dysregulation of the endothelin pathway in lymphangioleiomyomatosis with no direct effect on cell proliferation and migration. *Scientific Reports*, **2018**, 8, 14698	4.9	2
77	Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?. *Frontiers in Medicine*, **2021**, 8, 713698	4.9	2
76	Tuberous sclerosis complex for the pulmonologist. *European Respiratory Review*, **2021**, 30,	9.8	2
75	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. *European Respiratory Journal*, **2021**, 58,	13.6	2
74	Safety and tolerability of nintedanib in patients with progressive fibrosing interstitial lung diseases: data from the randomized controlled INBUILD trial.. *Respiratory Research*, **2022**, 23, 85	7.3	2
73	Subclinical venous access infection and clinical worsening in pulmonary arterial hypertension. *Journal of Heart and Lung Transplantation*, **2017**, 36, 369-370	5.8	1
72	Pulmonary fibrosis: "idiopathic" is not "cryptogenic". *European Respiratory Journal*, **2019**, 53,	13.6	1
71	Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801´mg Tablet Formulation: A Multinational Survey. *Pulmonary Therapy*, **2020**, 6, 93-105	3	1
70	Fibrose pulmonaire: dans quels cas et sur quels crit□es envisager une admission en r□animation ?. *Reanimation: Journal De La Societe De Reanimation De Langue Francaise*, **2013**, 22, 45-53		1
69	The Syndrome of Combined Pulmonary Fibrosis and Emphysema **2015**, 327-347		1
68	Pulmonary Vascular Disorders in Hereditary Hemorrhagic Telangiectasia. *Progress in Respiratory Research*, **2012**, 262-275		1

67	Pneumopathies □ō sinophiles : diagnostic et prise en charge. *Revue Francaise Diallergologie*, **2012**, 52, 128-133	0.2	1
66	Celiac disease revealed by diffuse alveolar hemorrhage and heart block. *Respiratory Medicine Extra*, **2006**, 2, 89-91		1
65	H□morragies alv□olaires. *Revue Des Maladies Respiratoires*, **2006**, 23, 31-38	0	1
64	Post hoc Analysis of Clinical Outcomes in Placebo- and Pirfenidone-Treated Patients with IPF Stratified by BMI and Weight Loss. *Respiration*, **2021**, 1-13	3.7	1
63	Diagnosis and monitoring of systemic sclerosis-associated interstitial lung disease using high-resolution computed tomography. *Journal of Scleroderma and Related Disorders*,2397198321106442.3		1
62	Pharmacological management196-217		1
61	Variability in Global Prevalence of Interstitial Lung Disease. *Frontiers in Medicine*, **2021**, 8, 751181	4.9	1
60	Diffuse bronchiectasis and airflow obstruction in granulomatosis with polyangiitis. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2018**, 35, 81-84	1.1	1
59	Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort. *Advances in Therapy*, **2021**, 39, 405	4.1	1
58	IC4: a new combined predictive index of mortality in idiopathic pulmonary fibrosis. *Panminerva Medica*, **2021**,	2	1
57	Idiopathic pulmonary fibrosis: Physician and patient perspectives on the pathway to care from symptom recognition to diagnosis and disease burden. *Respirology*, **2021**,	3.6	1
56	Pulmonary involvement in inflammatory myopathies **2019**, 68-89		1
55	Eosinophilic Pneumonia **2015**, 227-251		1
54	Combined pulmonary fibrosis and emphysema in alpha-1-antitrypsin deficiency. *Respiratory Medicine and Research*, **2021**, 79, 100819	1.4	1
53	Care Delivery Models and Interstitial Lung Disease: The Role of the Specialized Center. *Clinics in Chest Medicine*, **2021**, 42, 347-355	5.3	1
52	The progressive fibrotic phenotype in current clinical practice. *Current Opinion in Pulmonary Medicine*, **2021**, 27, 368-373	3	1
51	Epidemiology, Mortality and Healthcare Resource Utilization Associated With Systemic Sclerosis-Associated Interstitial Lung Disease in France. *Frontiers in Medicine*, **2021**, 8, 699532	4.9	1
50	Historical Patterns of Diagnosis, Treatments, and Outcome of Epilepsy Associated With Tuberous Sclerosis Complex: Results From TOSCA Registry. *Frontiers in Neurology*, **2021**, 12, 697467	4.1	1

49	Severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A prospective French multicenter cohort. *Journal of Heart and Lung Transplantation*, **2021**, 40, 1009-1018	5.8	1
48	Evolution from hypereosinophilic bronchiolitis to eosinophilic granulomatosis with polyangiitis following COVID-19: a case report. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 128, 11-12	2.2	1
47	European Respiratory Society International Congress 2021: highlights from best-abstract awardees. *Breathe*, **2022**, 18, 210176	1.8	1
46	Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics.. *Frontiers in Medicine*, **2021**, 8, 802989	4.9	1
45	Pirfenidone in Unclassifiable Interstitial Lung Disease: A Subgroup Analysis by Concomitant Mycophenolate Mofetil and/or Previous Corticosteroid Use.. *Advances in Therapy*, **2021**, 39, 1081	4.1	1
44	Vascularites pulmonaires. *Revue Des Maladies Respiratoires Actualites*, **2011**, 3, S67-S75	0	0
43	Malformations artï¿½rioveineuses pulmonaires et maladie de Rendu-Osler. *Revue Des Maladies Respiratoires Actualites*, **2009**, 1, 164-167	0	0
42	Automatic quantitative computed tomography measurement of longitudinal lung volume loss in interstitial lung diseases.. *European Radiology*, **2022**, 1	8	0
41	The Burden of Progressive-Fibrosing Interstitial Lung Diseases.. *Frontiers in Medicine*, **2022**, 9, 799912	4.9	0
40	French Vasculitis Study Group recommendations for the management of COVID-19 vaccination and prophylaxis in patients with systemic vasculitis.. *Presse Medicale*, **2021**, 51, 104107	2.2	0
39	Steroid alternatives for managing eosinophilic lung diseases. *Expert Opinion on Orphan Drugs*,	1.1	0
38	12q13.12q13.13 microdeletion encompassing ACVRL1 and SCN8A genes: Clinical report of a new contiguous gene syndrome. *European Journal of Medical Genetics*, **2019**, 62, 103565	2.6	0
37	Sjï¿½gren disease, not Sjï¿½gren's. *Arthritis and Rheumatology*, **2021**,	9.5	0
36	Hospital costs of Balloon Pulmonary Angioplasty (BPA) procedure and management for CTEPH patients: An observational study based on the French national hospital discharge database (PMSI). *PLoS ONE*, **2021**, 16, e0260483	3.7	0
35	Reply: The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 660-661	10.2	
34	Cohorte de patients atteints de pneumopathie interstitielle diffuse de forme progressive (hors fibrose pulmonaire idiopathique) (ï¿½tude PROGRESS)ï¿½sultats prï¿½minaires. *Revue Des Maladies Respiratoires Actualites*, **2020**, 12, 11-12	0	
33	Nouveau concept dï¿½PAF (pneumopathie interstitielle avec manifestations auto-immunes). *Revue Du Rhumatisme Monographies*, **2018**, 85, 146-152	0	
32	Interstitial Pneumonia With Autoimmune Features: An Update. *Archivos De Bronconeumologia*, **2018**, 54, 447-448	0.7	

31	Thoracic manifestations of segmental neurofibromatosis. *BMJ Case Reports*, **2017**, 2017,	0.9
30	P8 Pooled analysis of data from the TOMORROW and INPULSIS trials of nintedanib in IPF. *Thorax*, **2015**, 70, A78.1-A78	7.3
29	P279 Reduction In Disease Progression With Nintedanib In The Inpulsis Trials. *Thorax*, **2014**, 69, A196-A196	7.3
28	Malformations artérioveineuses pulmonaires. *Encyclopédie Médico-chirurgicale Pneumologie*, **2011**, 8, 1-10	
27	Malformations artérioveineuses pulmonaires. *EMC - Radiologie Et Imagerie Médicale - Cardiovasculaire - Thoracique - Cervicale*, **2012**, 7, 1-10	
26	Anticorps monoclonaux et pneumopathies interstitielles. *Revue Des Maladies Respiratoires Actualites*, **2009**, 1, S105-S108	0
25	Bronchite éosinophiles. *Revue Francaise Diallergologie Et Diimmunologie Clinique*, **2008**, 48, 196-200	
24	Bilan diagnostique des MAVP. *Revue Des Maladies Respiratoires*, **2007**, 24, 99-102	0
23	Nemaline myopathy revealed by respiratory failure in adults. *Respiratory Medicine Extra*, **2007**, 3, 127-129	
22	Traitement des pneumopathies interstitielles diffuses. *Revue Des Maladies Respiratoires*, **2006**, 23, 97-102	0
21	Valeur pronostique du test de marche de 6 minutes (TM6) chez des patients atteints de pneumopathies infiltrantes diffuses (PID) à forme progressive (PID-FP) hors fibrose pulmonaire idiopathique (FPI). *Revue Des Maladies Respiratoires Actualites*, **2022**, 14, 45	0
20	Lymphangioleiomyomatosis **2019**, 585-588	
19	Eosinphilic granulomatosis with polyangiitis **2019**, 188-209	
18	Survey of Physician's Knowledge, Attitudes, and Practices Regarding Idiopathic Pulmonary Fibrosis in Turkey. *Turkish Thoracic Journal*, **2020**, 21, 44-48	0.8
17	BOEHRINGER INGELHEIM - Fibroses pulmonaires : maladies pulmonaires ou maladies systémiques ?. *Revue Des Maladies Respiratoires Actualites*, **2020**, 12, S58-S63	0
16	Effect of nintedanib on disease progression in the INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF). *Pneumologie*, **2017**, 71, S1-S125	0.5
15	Effect of nintedanib on decline in forced vital capacity (FVC) over time in the INPULSIS trials in patients with idiopathic pulmonary fibrosis (IPF). *Pneumologie*, **2017**, 71, S1-S125	0.5
14	Twenty-four week decline in forced vital capacity (FVC) predicts mortality at week 52 in the INPULSIS trials. *Pneumologie*, **2017**, 71, S1-S125	0.5

13	Classification anatomo-clinique des pneumopathies interstitielles diffuses idiopathiques : synthèse et perspectives. *Bulletin De LiAcademie Nationale De Medecine*, **2010**, 194, 327-342	0.1
12	mTOR inhibitors for the management of difficult lymphangioma in adults. *Respiratory Medicine and Research*, **2020**, 77, 8-10	1.4
11	Granulomatose sarcoïdosique nécrosante : présentation clinique et évolution. *Revue De Medecine Interne*, **2020**, 41, A35-A36	0.1
10	New therapeutic strategies in lung vasculitis. *Current Opinion in Pulmonary Medicine*, **2020**, 26, 496-506	3
9	Fibrose pulmonaire idiopathique au sein de la cohorte RaDiCo-PID. *Revue DiEpidemiologie Et De Sante Publique*, **2020**, 68, S87-S88	0.6
8	Inhaled Treprostinil in Group 3 Pulmonary Hypertension. *New England Journal of Medicine*, **2021**, 384, 1869	59.2
7	Expectations about treatment of idiopathic pulmonary fibrosis: Comparative survey of patients, carers and physicians (the RESPIR French survey). *Respiratory Medicine and Research*, **2021**, 79, 100811	1.4
6	Actualités dans les pneumopathies interstitielles diffuses. *Revue Des Maladies Respiratoires Actualites*, **2021**, 13, 1S104-1S107	0
5	Développement d'algorithmes pour identifier les patients atteints de pneumopathie interstitielle diffuse fibrosante progressive (PID-FP) en France (étude PROGRESS). *Revue DiEpidemiologie Et De Sante Publique*, **2019**, 67, S181-S182	0.6
4	Exploration du parcours de vie des patients/aidants dans la fibrose pulmonaire idiopathique, à travers une étude ethnographique. *Revue Des Maladies Respiratoires Actualites*, **2021**, 13, 190	0
3	SYNTHÈSE N° 2: Le concept de pneumopathie interstitielle avec manifestations auto-immunes. *Revue Des Maladies Respiratoires Actualites*, **2018**, 10, 65-68	0
2	Impact of Gender on the Characteristics of Patients with Idiopathic Pulmonary Fibrosis Included in the RaDiCo-ILD Cohort. *Respiration*, **2021**, 1-12	3.7
1	Smoking-Related Interstitial Lung Disease **2022**, 242-256	